MeiraGTx Stock Dips 5.5% After Weekly Slide; FDA Designation and Funding in Focus
MeiraGTx shares fell 5.5% Friday to $9.40, ending a 4.3% weekly drop, as the company reported a Q1 net loss of $46.3 million and advanced regulatory filings for key gene therapies.
Markets
